PULSE BIOSCIENCES, INC. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Pulse Biosciences completed enrollment of 100 patients in the PRECISE-BTN clinical study evaluating nPulse Vybrance for symptomatic benign thyroid nodules across three U.S. sites (Sarasota Memorial, NYU Langone, Weill Cornell) in approximately 12 months. The enrollment doubled the original 50-patient design. The first enrolled patient completed the 12-month follow-up visit in August 2026; preliminary data presentation at a medical conference is planned, with full data expected upon completion of all patients' 12-month follow-ups.
Why this rating
Clinical enrollment completion is meaningful for early-stage medtech; double the planned cohort strengthens dataset. Routine for development stage; no revenue, regulatory, or financing impact disclosed yet.
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.